Zoetis (NYSE:ZTS) Posts Earnings Results, Beats Expectations By $0.08 EPS

Zoetis (NYSE:ZTS - Get Free Report) announced its earnings results on Tuesday. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08, Zacks reports. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. During the same quarter in the previous year, the business earned $1.38 EPS. The business's quarterly revenue was up 1.4% compared to the same quarter last year. Zoetis updated its FY 2025 guidance to 6.200-6.30 EPS.

Zoetis Trading Down 4.4 %

Shares of Zoetis stock opened at $151.12 on Tuesday. The stock has a market capitalization of $67.43 billion, a P/E ratio of 27.89, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis has a 12-month low of $139.70 and a 12-month high of $200.33. The company has a 50-day simple moving average of $158.17 and a 200 day simple moving average of $166.80.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.32%. The ex-dividend date is Monday, April 21st. Zoetis's dividend payout ratio (DPR) is 36.56%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,862 shares of company stock worth $312,254. Corporate insiders own 0.16% of the company's stock.

Hedge Funds Weigh In On Zoetis

An institutional investor recently raised its stake in Zoetis stock. Brighton Jones LLC boosted its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 180.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,629 shares of the company's stock after purchasing an additional 2,978 shares during the period. Brighton Jones LLC's holdings in Zoetis were worth $754,000 as of its most recent filing with the SEC. Institutional investors own 92.80% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus cut their price target on shares of Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a report on Monday, April 14th. StockNews.com raised shares of Zoetis from a "hold" rating to a "buy" rating in a research note on Friday, March 7th. Barclays increased their price target on shares of Zoetis from $242.00 to $244.00 and gave the stock an "overweight" rating in a research note on Friday, February 14th. Piper Sandler raised their target price on Zoetis from $200.00 to $205.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Finally, Morgan Stanley decreased their price target on Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $214.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.